ruthenium chloride (rucl3) has been researched along with cytochrome c-t in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anzellotti, A; Rieber, M; Sánchez-Delgado, RA; Strasberg Rieber, M | 1 |
| Bernini, C; Cini, R; Corbini, G; Giudice, PL; Massai, L; Messori, L; Owens, NF; Scaletti, F; Tamasi, G | 1 |
2 other study(ies) available for ruthenium chloride (rucl3) and cytochrome c-t
| Article | Year |
|---|---|
Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Caspase 3; Caspases; Cisplatin; Clotrimazole; Combined Modality Therapy; Cytochromes c; Drug Synergism; Enzyme Activation; ErbB Receptors; Humans; Ketoconazole; Membrane Proteins; Mitochondria; Neoplasms; Poly(ADP-ribose) Polymerases; Ruthenium Compounds; Spheroids, Cellular; Superoxide Dismutase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2004 |
Synthesis, spectroscopic and DFT structural characterization of two novel ruthenium(III) oxicam complexes. In vivo evaluation of anti-inflammatory and gastric damaging activities.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Cell Survival; Coordination Complexes; Cytochromes c; Drug Stability; Edema; Hindlimb; Humans; Ligands; Male; Muramidase; Piroxicam; Protein Binding; Quantum Theory; Rats; Rats, Wistar; Ruthenium Compounds; Serum Albumin; Solubility | 2014 |